autologous CAR-T, including Glypican 3 (GPC3) targeting CAR-Ts in hepatocellular carcinoma. AZD5851, currently in Phase I, is being developed globally, and AZD7003 / C-CAR031 is being co-developed with AbelZeta in China where it...
Brazil (COV003), and South Africa (COV005). A further phase 1/2 trial has recently been initiated in Kenya and is not reported here. The immunogenicity results from the phase 1/
and AstraZeneca (NYSE:AZN) today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience’s anti-cancer drug ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound...
clearly that’s ungated a number of additional studies and so we continue to invest in R&D. I think we’ve been fairly consistent around how much we want to invest in R&D on an ongoing basis in the sort of low-20 range and we’re sort of consistent...
At AACR 2023, the Company presented preliminary safety, efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) data from an investigator-initiated trial (IIT) in China showing promising anti-tumor activity and...
Investigator-led studies highlight the value of collaboration in new areas of unmet need AstraZeneca’s broad network of industry and academic partners is broadening exploration of the company’s pipeline into additional tumour types where unmet patient needs remain. The US...
Professor Charlie Strange, MD, Medical University of South Carolina, US and investigator in the EROS study, said: "A key treatment goal in COPD is to avoid exacerbations that may lead to increased risk of future exacerbations, possib...
AstraZeneca Pharmaceuticals LP MORE ON THIS TOPIC GLP-1 GLP-1s Potentially ‘Transformative’ but Could Lead to ‘Distorted’ Obesity Care: WHO December 19, 2024 · 2 min read · Tristan Manalac Sickle cell disease Vertex, Beam Report SC...
• Arm B1: Imfinzi + Investigator's choice of chemo • Arm B2: Imfinzi + danvatirsen + Investigator's choice of chemo • Arm B3: Imfinzi + oleclumab + Investigator's choice of chemo • Arm B4: MEDI5752 Primary endpoint: • Safety & tolerability ...